%PDF-1.4
%
33 0 obj
<>
endobj
35 0 obj
<>stream
2019-11-08T11:55:01-05:00
QuarkXPress(R) 13.0
2024-03-29T03:15:14-07:00
2024-03-29T03:15:14-07:00
QuarkXPress(R) 13.0
application/pdf
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
%%DocumentProcessColors: Magenta Yellow Black
%%EndComments
uuid:de26397e-1dd1-11b2-0a00-5b08271d5700
uuid:de263983-1dd1-11b2-0a00-bf0000000000
endstream
endobj
5 0 obj
<>]>>
endobj
30 0 obj
<>
endobj
31 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/TrimBox[0 0 585 783]/Type/Page/u2pMat[1 0 0 -1 0 783]/xb1 0/xb2 585/xt1 0/xt2 585/yb1 0/yb2 783/yt1 0/yt2 783>>
endobj
32 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/TrimBox[0 0 585 783]/Type/Page/u2pMat[1 0 0 -1 0 783]/xb1 0/xb2 585/xt1 0/xt2 585/yb1 0/yb2 783/yt1 0/yt2 783>>
endobj
42 0 obj
[47 0 R]
endobj
43 0 obj
<>stream
HWoܸ~7A {9)8=H-[wU ;$P:jCYf|7#|wv{?g6Z)mѐ}h߿duIcuˮZΆo+_wκkAC#ђ1g!6g[r@cBǭ@j@cE a-4x 튞e9|i?gs%J>_)fRoo#XINKa6{u!
ݟ)odת^5J@fgZxa\VVo
[#/?0cXzvTc9%Tv!4Q(d;lԔ{evl60+0ys(cˊRV RfMfU§|̀l,Hwi.0:ZWA9
WO>.`ت)EGk-XfD0G²:$}k9xjG理{